Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-04-28
Recursion Pharmaceuticals, Inc.
Recursion is a clinical-stage biotech that uses its Recursion OS, automated labs, and proprietary data to discover and develop medicines internally and with partners.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Proof Gating Masks a Real Option Engine
This is a clinical-validation story first and an AI story second. The upside comes from turning a differentiated discovery stack into repeatable medicines and cleaner economics, not from selling software.

Analysis

Thesis
Recursion is a proof-gated drug factory rather than a thin AI wrapper: if 2026-2027 human data show Recursion OS can repeatedly create clinically usable assets, the business can shift from cash-backed option value to a stronger mix of owned product revenue, milestones, royalties, and externally financed programs by 2031.
Last Economy Alignment
It benefits from cheaper cognition because it owns data, labs, compute, and drug rights; the main bottleneck is clinical proof, not software price compression.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.9x (from 5 most recent analyses)
Reasoning
The upside case is a quality change in revenue, not just more of the same. If one owned asset reaches early commercialization or value-bearing licensing and the platform also produces a steadier cadence of milestones, royalties, and better-structured partner deals, investors can value the company as a hybrid commercial biotech and discovery engine rather than a cash-burning experiment. I cap the rerating because regulatory and translation risk still dominate.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The central risk is still translation. Recursion has more real control points than most AI biotechs, but the market will not fully reward those assets until human data and regulators show the engine can repeatedly produce clinically valuable programs. If proof slips, the company can remain a cash-consuming platform with lumpy collaboration revenue and eventual dilution pressure.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.56
They own the data, labs, compute, and drug rights that get more valuable as AI makes discovery faster and cheaper. The risk is simple: if those tools do not keep producing medicines that work in people, the advantage shrinks fast.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.50
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case